Drugs and brands

Foundayo

Every GLP-1 the FDA has approved, and the active ingredient inside each one.

What is Foundayo?

Orforglipron tablets from Eli Lilly, FDA-approved April 2026 as the first oral non-peptide GLP-1 receptor agonist.

Patients take one tablet a day, with or without food. Its arrival matters commercially: a pill with no cold chain and no needle changes what a telehealth seller has to justify charging for.

Related reading: Foundayo (Orforglipron): the GLP-1 Pill With No Fasting Rule

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where Foundayo comes up on this site

On GLP Watchdog, Foundayo comes up in 20 research articles, 50 seller reviews and 4 tools.

Other terms under Drugs and brands

Where the evidence lives